Condition
Recurrent Childhood Oligodendroglioma
Total Trials
3
Recruiting
0
Active
0
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
200%
2 of 1 completed with results
Key Signals
2 with results50% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (2)
P 1 (1)
Trial Status
Completed1
Withdrawn1
Terminated1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT02194452Not ApplicableWithdrawn
Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors
NCT02175745Not ApplicableTerminated
18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent Gliomas
NCT00095940Phase 1Completed
Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors
Showing all 3 trials